14 assets in Atypical Teratoid Rhabdoid Tumor

Therapeutic assets addressing Atypical Teratoid Rhabdoid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Celecoxib Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Cyclophosphamide Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Cytarabine Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Etoposide Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Fenofibric Acid Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Irinotecan Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Thalidomide Atypical Teratoid Rhabdoid Tumor	Medical University of Vienna	P2	CCC (53)
Atezolizumab Atypical Teratoid Rhabdoid Tumor	National Cancer Institute (NCI)	P1/2	CCC (48)
Fludeoxyglucose Atypical Teratoid Rhabdoid Tumor	National Cancer Institute (NCI)	P1/2	CCC (48)
Tiragolumab Atypical Teratoid Rhabdoid Tumor	National Cancer Institute (NCI)	P1/2	CCC (48)
21.15.gpc3-car t cells Atypical Teratoid Rhabdoid Tumor	Baylor College of Medicine	P1	CC (43)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Atypical Teratoid Rhabdoid Tumor	Sun Yat-sen University	P1	CC (43)
b7-h3-car t cells Atypical Teratoid Rhabdoid Tumor	St. Jude Children's Research Hospital	P1	CC (43)
Onc 206 Atypical Teratoid Rhabdoid Tumor	Jazz Pharmaceuticals	P1	CC (43)